Valuation Takeda Pharmaceutical Company Limited

Stocks

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-08-07 EDT			5-day change	1st Jan Change
5,540.00 ^JPY	+2.12%		+0.49%	+14.58%

08-05	Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL	MT
08-05	Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1	CI

Company Valuation: Takeda Pharmaceutical Company Limited

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	5,423,454	6,762,204	6,564,378	6,749,675	8,948,061	8,846,043	-	-
Change	-	24.68%	-2.93%	2.82%	32.57%	-1.14%	-	-
Enterprise Value (EV) ¹	8,919,170	10,611,015	10,950,330	10,725,175	5,130,461	12,772,405	12,610,474	12,281,677
Change	-	18.97%	3.2%	-2.06%	-52.16%	148.95%	-1.27%	-2.61%
P/E	23.8x	21.3x	45.4x	64.6x	46.4x	44.5x	27.6x	22.2x
PBR	0.95x	1.06x	0.9x	1x	1.2x	1.18x	1.17x	1.16x
PEG	-	0.5x	-0.8x	-2.5x	0.6x	21.65x	0.5x	0.9x
Capitalization / Revenue	1.52x	1.68x	1.54x	1.47x	1.99x	1.89x	1.86x	1.82x
EV / Revenue	2.5x	2.63x	2.57x	2.34x	1.14x	2.74x	2.66x	2.52x
EV / EBITDA	8.54x	9.19x	11.6x	9.71x	4.54x	9.49x	8.9x	8.25x
EV / EBIT	19.4x	21.6x	51.1x	31.3x	12.6x	28.8x	21x	17.3x
EV / FCF	8.92x	28.7x	43.4x	15.5x	8.14x	16.7x	16.5x	14.7x
FCF Yield	11.2%	3.49%	2.31%	6.43%	12.3%	5.98%	6.07%	6.8%
Dividend per Share ²	180	180	188	196	200	204.4	208.4	214.6
Rate of return	5.15%	4.14%	4.49%	4.44%	3.53%	3.69%	3.76%	3.87%
EPS ²	147.1	204.3	92.09	68.36	122	124.5	200.7	249.5
Distribution rate	122%	88.1%	204%	287%	164%	164%	104%	86%
Net sales ¹	3,569,006	4,027,478	4,263,762	4,581,600	4,505,700	4,668,456	4,747,030	4,870,775
EBITDA ¹	1,043,995	1,154,905	942,077	1,103,982	1,129,888	1,345,287	1,416,570	1,488,570
EBIT ¹	460,844	490,505	214,100	342,600	408,800	443,247	599,826	708,213
Net income ¹	230,059	317,017	144,067	107,900	191,800	190,630	316,308	383,303
Net Debt ¹	3,495,716	3,848,811	4,385,952	3,975,500	-3,817,600	3,926,362	3,764,431	3,435,634
Reference price ²	3,498.00	4,350.00	4,184.00	4,413.00	5,664.00	5,540.00	5,540.00	5,540.00
Nbr of stocks (in thousands)	1,550,444	1,554,530	1,568,924	1,529,498	1,579,813	1,596,759	-	-
Announcement Date	5/11/22	5/11/23	5/9/24	5/8/25	5/13/26	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
TAKEDA PHARMACEUTICAL COMPANY LIMITED	44.5x	2.74x	9.49x	3.69%	56.09B
ELI LILLY AND COMPANY	33.6x	12.29x	24.81x	0.58%	1,057B
JOHNSON & JOHNSON	28.84x	-	-	2.07%	625B
ABBVIE INC.	32.34x	7.35x	15.3x	2.81%	435B
ROCHE HOLDING AG	20.47x	4.85x	12.02x	2.72%	363B
NOVARTIS AG	22.14x	5.72x	14.28x	2.8%	296B
ASTRAZENECA PLC	20.58x	4.25x	12.07x	2.07%	249B
AMGEN INC.	25.76x	6.79x	12.06x	2.45%	222B
NOVO NORDISK A/S	13.84x	4.97x	10.44x	3.68%	209B
GILEAD SCIENCES, INC.	-41.38x	5.93x	33.46x	2.47%	165B
Average	20.07x	6.10x	15.99x	2.53%	367.69B
Weighted average by Cap.	24.74x	7.99x	18.15x	2.01%